Search results for " Humans"

showing 10 items of 2466 documents

Impact of viable CD45 cells infused on lymphocyte subset recovery after unrelated cord blood transplantation in children

2010

International audience; We studied lymphocyte recovery in 88 children who consecutively underwent unrelated cord blood transplantation for malignant (n = 64) or nonmalignant (n = 24) diseases. All children but 3 received myeloablative conditioning regimens with pretransplant antithymocyte globulin. Median age was 5.6 years (0.1-18 years) and median follow-up was 40 months (10-136 months). The median dose of infused viable CD45(+) cells (vCD45) was 3.35 × 10(7)/kg with a ratio infused vCD45/collected total nucleated cell at 0.46. Immunologic endpoints were: time to achieve CD3(+) >500 and 1500/mm(3), CD4(+) >500/mm(3), CD8(+) >250/mm(3), CD19(+) >200/mm(3), natural killer >100/mm(3). These e…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyLymphocyteMESH: Antigens CD/analysisCell Count[SDV.GEN] Life Sciences [q-bio]/GeneticsMESH : Child PreschoolGastroenterology0302 clinical medicineMESH : ChildMESH: Child[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyChildChildrenMESH : Lymphocyte Count0303 health sciencesMESH : Cell SurvivalbiologyIncidence (epidemiology)Graft Survival[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematology3. Good healthMESH: Hematologic Diseases/therapy Humansmedicine.anatomical_structureQuartileMESH: Cell SurvivalMESH: Cord Blood Stem Cell Transplantation/methodsLymphocytes recoveryChild PreschoolMESH : Immunophenotyping[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH: Infant KineticsCord Blood Stem Cell Transplantationmedicine.medical_specialtyMESH: Lymphocyte CountGlobulinMESH: ImmunophenotypingAdolescent[SDV.IMM] Life Sciences [q-bio]/ImmunologyCell SurvivalContext (language use)MESH : Hematologic Diseases/therapy HumansCD19Immunophenotyping03 medical and health sciencesMESH : Lymphocyte Subsets/cytologyAntigens CDInternal medicineMESH : AdolescentmedicineHumansLymphocyte CountMESH : Infant KineticsMESH : Antigens CD45* Cell Count030304 developmental biologyMESH: AdolescentTransplantation[SDV.GEN]Life Sciences [q-bio]/GeneticsUmbilical cord blood transplantationMESH : Graft Survival/immunologybusiness.industryUmbilical Cord Blood TransplantationMESH: Child PreschoolMESH : Cord Blood Stem Cell Transplantation/methodsInfantMESH : Antigens CD/analysisHematologic DiseasesLymphocyte SubsetsSurgeryMESH: Lymphocyte Subsets/cytologyKineticsbiology.proteinMESH: Antigens CD45* Cell CountLeukocyte Common Antigensbusiness[ SDV.GEN ] Life Sciences [q-bio]/GeneticsMESH: Graft Survival/immunologyCD8030215 immunology
researchProduct

Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic st…

2017

IF 7.702; International audience; The survival of patients with diffuse large B-cell lymphoma has increased during the last decade as a result of addition of anti-CD20 to anthracycline-based chemotherapy. Although the trend is encouraging, there are persistent differences in survival within and between the USA and European countries suggesting that non-biological factors play a role. Our aim was to investigate the influence of such factors on relative survival of patients with diffuse large B-cell lymphoma. We conducted a retrospective, multicenter, registry-based study in France on 1165 incident cases of diffuse large B-cell lymphoma between 2002 and 2008. Relative survival analyses were p…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyMale0301 basic medicinePediatricsMultivariate analysisMESH: RegistriesMESH : AgedMESH: ComorbidityComorbidityMESH : Lymphoma Large B-Cell DiffuseMESH: Aged 80 and over0302 clinical medicineInternational Prognostic IndexMESH : ChildMESH: ChildMESH : Population Surveillance[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleRegistriesYoung adultChildAged 80 and overMESH: AgedMESH: Middle AgedMESH : PrognosisRelative survivalMESH: Patient Outcome Assessment[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyArticlesHematologyMiddle AgedMESH : AdultPrognosisMESH : Patient Outcome Assessment3. Good healthMESH: Young AdultPopulation SurveillanceMESH: Survival Analysis030220 oncology & carcinogenesisMESH : ComorbidityMarital statusFemaleFranceLymphoma Large B-Cell DiffuseNon-Hodgkin LeukemiaAdultmedicine.medical_specialtyAdolescentMESH : MaleMESH: Factor Analysis StatisticalMESH : Young AdultMESH : Factor Analysis StatisticalMESH: PrognosisMESH: Population SurveillanceMESH: Social ClassYoung Adult03 medical and health sciencesMESH : AdolescentInternal medicineMESH : Social ClassmedicineHumansMESH : Middle AgedMESH : Aged 80 and overMESH : FranceSurvival analysisAgedMESH: AdolescentMESH: Humansbusiness.industryMESH : HumansMESH: Adultmedicine.diseaseSurvival AnalysisComorbidityMESH: MalePatient Outcome AssessmentMESH: France030104 developmental biologySocial ClassMESH: Lymphoma Large B-Cell DiffuseMESH : Survival AnalysisFactor Analysis StatisticalbusinessMESH: FemaleDiffuse large B-cell lymphomaMESH : RegistriesHaematologica
researchProduct

Import of norovirus infections in the Netherlands and Ireland following pilgrimages to Lourdes, 2008--preliminary report.

2008

International audience; Between mid-September and 19 October 2008, nine clusters of norovirus infection involving around 90 primary cases and over a hundred secondary cases were identified in patients from the Netherlands, Ireland, Italy and France, linked to pilgrimage to Lourdes, France.

[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMESH : NetherlandsMESH : NorovirusMESH : HumansMESH : Risk Factors[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMESH : IncidenceMESH : GastroenteritisMESH : TravelMESH : Population SurveillanceMESH : Creutzfeldt-Jakob SyndromeMESH : Disease OutbreaksMESH : Caliciviridae InfectionsMESH : Risk AssessmentMESH : FranceMESH : Ireland
researchProduct

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

2016

Seuls les 100 premiers auteurs dont les auteurs INRA ont été entrés dans la notice. La liste complète des auteurs et de leurs affiliations est accessible sur la publication.; International audience; In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues…

[SDV]Life Sciences [q-bio]autophagosomeReview Articleddc:616.07stressstreLC3MESH: AnimalsSettore MED/49 - Scienze Tecniche Dietetiche ApplicateSettore BIO/06 - Anatomia Comparata E Citologiachaperone-mediated autophagyComputingMilieux_MISCELLANEOUSSettore BIO/11Pharmacology. TherapySettore BIO/13standards [Biological Assay]autolysosomeMESH: Autophagy*/physiologylysosomemethods [Biological Assay]Biological AssaySettore BIO/17 - ISTOLOGIAErratumHumanBiochemistry & Molecular BiologySettore BIO/06physiology [Autophagy]Chaperonemediated autophagy[SDV.BC]Life Sciences [q-bio]/Cellular BiologyNOautophagy guidelines molecular biology ultrastructureautolysosome; autophagosome; chaperone-mediated autophagy; flux; LC3; lysosome; macroautophagy; phagophore; stress; vacuoleMESH: Biological Assay/methodsMESH: Computer Simulationddc:570Autolysosome Autophagosome Chaperonemediated autophagy Flux LC3 Lysosome Macroautophagy Phagophore Stress VacuoleAutophagyAnimalsHumansComputer SimulationSettore BIO/10ddc:612BiologyphagophoreMESH: HumansvacuoleAnimalLC3; autolysosome; autophagosome; chaperone-mediated autophagy; flux; lysosome; macroautophagy; phagophore; stress; vacuole; Animals; Biological Assay; Computer Simulation; Humans; Autophagy0601 Biochemistry And Cell BiologyfluxmacroautophagyMESH: Biological Assay/standards*Human medicineLC3; autolysosome; autophagosome; chaperone-mediated autophagy; flux; lysosome; macroautophagy; phagophore; stress; vacuole
researchProduct

Confidencialitat en Treball Social

2022

El document forma part dels materials docents programats mitjançant l'ajut del Servei de Política Lingüística de la Universitat de València. La confidencialitat en Treball Social és un element clau en les intervencions professionals i és d'obligat compliment segons Codi Deontològic del Consejo General de Trabajo Social Confidentiality in Social Work is a key element in professional interventions and is mandatory according to the Code of Ethics of the General Council of Social Work

acceptacióconfidencialitatUNESCO::SOCIOLOGÍAsecret professionaldrets humans
researchProduct

DNA damage response at telomeres boosts the transcription of SARS-CoV-2 receptor ACE2 during aging

2021

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus disease 2019 (COVID-19), known to be more common in the elderly, who also show more severe symptoms and are at higher risk of hospitalization and death. Here, we show that the expression of the angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 cell receptor, increases during aging in mouse and human lungs. ACE2 expression increases upon telomere shortening or dysfunction in both cultured mammalian cells and in vivo in mice. This increase is controlled at the transcriptional level, and Ace2 promoter activity is DNA damage response (DDR)-dependent. Both pharmacological global DDR inhibition of ATM kin…

ace2; covid-19; dna damage response; aging; telomere; aged; angiotensin-converting enzyme 2; animals; humans; mice; sars-cov-2; aging; covid-19; dna damage; telomeremiceCoronavirus disease 2019 (COVID-19)DNA damageSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BiologySettore MED/08 - Anatomia PatologicaBiochemistry03 medical and health sciences0302 clinical medicineDownregulation and upregulationPromoter activityTranscription (biology)angiotensin-converting enzyme 2GeneticsSettore MED/05 - Patologia ClinicaReceptorhumansMolecular Biology030304 developmental biology0303 health sciencestelomereAce2 aging COVID-19DNA damage response telomereagingace23. Good healthTelomereCell biologybody regionsdna damage responseanimalsagedsars-cov-2covid-19Angiotensin-converting enzyme 2Cancer researchdna damagehormones hormone substitutes and hormone antagonists030217 neurology & neurosurgery
researchProduct

Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study

2021

This study evaluates the frequency and causes of dolutegravir (DTG) discontinuation along 5 years of follow-up, in both antiretroviral treatment (ART)-naive and experienced people living with HIV (PLWH). This is a prospective multi-center cohort study enrolling PLWH on DTG from July 2014 until November 2020. DTG-durability was investigated using the Kaplan-Meier survival curve. The Cox proportional-hazards model was used for estimating the hazard ratio (HR) of DTG discontinuation for any cause, and for adverse events (AEs). Nine hundred sixty-three PLWH were included, 25.3% were women and 28.0% were ART-naive. Discontinuations for any causes were 10.1 [95% confidence interval (95% CI) 8.9-1…

adverse events; dolutegravir; durability; HIV; safety; toxicity; virolgical failure; Cohort Studies; Female; Heterocyclic Compounds 3-Ring; Humans; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Anti-HIV Agents; HIV InfectionssafetyPediatricsmedicine.medical_specialtySettore MED/17 - Malattie InfettivePyridonesAnti-HIV AgentsOxazineHuman immunodeficiency virus (HIV)adverse eventHIV Infectionsvirolgical failurePyridonemedicine.disease_cause3-RingHIV Infections.PiperazinesCohort Studieschemistry.chemical_compoundHeterocyclic CompoundsHIV; adverse events; dolutegravir; durability; safety; toxicity; virolgical failureOxazinesAntiretroviral treatmentMedicineHumansProspective StudiesAdverse effectPiperazinebusiness.industryPublic Health Environmental and Occupational HealthHIVtoxicityAnti-HIV AgentMiddle Agedadverse eventsDiscontinuationdolutegravirvirolgical failure.Prospective StudieInfectious DiseaseschemistryDolutegravirdurabilityObservational studyFemaleCohort StudiebusinessHeterocyclic Compounds 3-RingHuman
researchProduct

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

2016

Introduction: Osteonecrosis of the jaw (ONJ) is a clinically important, potentially painful and debilitating condition, which can affect the quality of life of cancer patients. Since 2003, ONJ appeared as a Bisphosphonate(BP)-related class effect, and the term Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) was widespread. Areas Covered: Under discussion in this review is the fact that ONJ cases have been reported after treatment including antiangiogenic agents and other “targeted therapy”, with and without BPs. Consequently, the comprehensive term Medication-Related Osteonecrosis of the Jaw (MRONJ) has been introduced. The clinical aspects and the prognosis of ONJ associated with t…

aflibercept; bevacizumab; Bisphosphonate; Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ); denosumab; everolimus; Medication-Related Osteonecrosis of the Jaw (MRONJ); Osteonecrosis of the jaw (ONJ); sunitinib; temsirolimus; Angiogenesis Inhibitors; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Humans; Jaw Diseases; Molecular Targeted Therapy; Neoplasms; Osteonecrosis; Quality of Life; Risk Assessment; Pharmacology (medical)Oncologysunitinibmedicine.medical_treatmentAngiogenesis InhibitorstemsirolimuTargeted therapyAntineoplastic Agent0302 clinical medicineNeoplasmsPharmacology (medical)Molecular Targeted TherapyJaw DiseaseafliberceptOsteonecrosisGeneral MedicineDenosumab030220 oncology & carcinogenesisOsteonecrosiBisphosphonate-Associated Osteonecrosis of the JawAngiogenesis InhibitorHumanmedicine.drugmedicine.medical_specialtyBevacizumabAntineoplastic AgentsbevacizumabRisk AssessmentBisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)Medication-Related Osteonecrosis of the Jaw (MRONJ)03 medical and health sciencesInternal medicinemedicineBisphosphonateHumansBisphosphonate-associated osteonecrosis of the jawbusiness.industryeverolimuCancerdenosumab030206 dentistryBisphosphonatemedicine.diseaseOsteonecrosis of the jaw (ONJ)Quality of LifeNeoplasmJaw DiseasesOsteonecrosis of the jawbusinessJaw DiseasesExpert Opinion on Drug Safety
researchProduct

Bone marrow-derived progenitors are greatly reduced in patients with severe COPD and low-BMI.

2009

Chronic obstructive pulmonary disease (COPD) patients have reduced circulating hemopoietic progenitors. We hypothesized that severity of COPD parallels the decrease in progenitors and that the reduction in body mass index (BMI) could be associated with more severe bone marrow dysfunction. We studied 39 patients with moderate to very severe COPD (18 with low-BMI and 21 with normal-BMI) and 12 controls. Disease severity was associated to a greater reduction in circulating progenitors. Proangiogenetic and inflammatory markers correlated with disease severity parameters. Compared to normal-BMI patients, low-BMI patients showed: greater reduction in circulating progenitors; higher VEGF-A, VEGF-C…

aged; analysis of variance; antigens; blood; blood cell count; body mass index; bone marrow transplantation; case-control studies; cd; chronic obstructive; chronic obstructive pulmonary disease; colony-forming units assay; creatine kinase; cytokines; endothelial cells; enzyme-linked immunosorbent assay; fat-free mass; female; humans; intercellular signaling peptides and proteins; lactate dehydrogenases; low-bmi copd; male; metabolism; methods; middle aged; normal-bmi copd; physiology; physiopathology/surgery; pulmonary disease; severity of illness index; statistics as topicMalePathologyPhysiologyStatistics as TopicCD34GastroenterologySeverity of Illness IndexBody Mass IndexPulmonary Disease Chronic Obstructiveantigenslow-bmi copdnormal-bmi copdCreatine Kinasepulmonary diseaseBone Marrow TransplantationCOPDchronic obstructiveGeneral NeuroscienceRespiratory diseaseMiddle Agedcdfat-free massHaematopoiesismedicine.anatomical_structurephysiopathology/surgeryCytokinesIntercellular Signaling Peptides and ProteinsFemalePulmonary and Respiratory Medicinemedicine.medical_specialtyEnzyme-Linked Immunosorbent Assaymacromolecular substancesSettore MED/10 - Malattie Dell'Apparato Respiratoriochronic obstructive pulmonary diseasemethodsColony-Forming Units AssayChronic obstructive pulmonary disease low-BMI COPD normal-BMI COPD fat-free massbloodAntigens CDInternal medicineSeverity of illnessmedicineHumansProgenitor cellLactate DehydrogenasesAgedAnalysis of Variancebusiness.industryCase-control studyEndothelial Cellsmedicine.diseaseBlood Cell CountCase-Control StudiesBone marrowbusinessmetabolismRespiratory physiologyneurobiology
researchProduct

Dret a l´alimentació

2019

El document forma part dels materials docents programats mitjançant l'ajut del Servei de Política Lingüística de la Universitat de València Dret a l´alimentació. Presentació de Powerpoint Right to Food. Power Point presentation

alimentacióUNESCO::CIENCIAS JURÍDICAS Y DERECHOdrets humans
researchProduct